Amazon Reportedly Negotiating $7 Billion Acquisition of AI Startup Decart
The company builds tools to switch between AI chips and creates world models.
Already have an account? Sign in.
The company builds tools to switch between AI chips and creates world models.
Early trial data show First Tracks’ ANB033 reduced intestinal damage and symptoms during a gluten challenge. Company plans late-stage development in 2027.
RYZ101 delivered a statistically significant PFS improvement in the Phase 3 ACTION-1 trial for SSTR+ GEP-NETs after Lu177 therapy. Safety consistent with prior data.
BofA upgraded Salesforce to Buy and lifted its price target to $285, arguing AI will deepen dependence on the platform rather than replace it.
Be the first to know when deals break, stocks move, or biotech headlines hit.